ES2057756T3 - Utilizacion del acido 3-oxigermilpropionico para tratar y prevenir enfermedades de autoinmunidad-diabetes dependientes. - Google Patents

Utilizacion del acido 3-oxigermilpropionico para tratar y prevenir enfermedades de autoinmunidad-diabetes dependientes.

Info

Publication number
ES2057756T3
ES2057756T3 ES91301646T ES91301646T ES2057756T3 ES 2057756 T3 ES2057756 T3 ES 2057756T3 ES 91301646 T ES91301646 T ES 91301646T ES 91301646 T ES91301646 T ES 91301646T ES 2057756 T3 ES2057756 T3 ES 2057756T3
Authority
ES
Spain
Prior art keywords
sub
oxygermyl
propionic acid
treat
ogp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91301646T
Other languages
English (en)
Inventor
Kiichi C O Sanwa Kagaku Sawai
Masayasu C O Sanwa Kaga Kurono
Takahiko C O Sanwa Kaga Mitani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanwa Kagaku Kenkyusho Co Ltd
Original Assignee
Sanwa Kagaku Kenkyusho Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanwa Kagaku Kenkyusho Co Ltd filed Critical Sanwa Kagaku Kenkyusho Co Ltd
Application granted granted Critical
Publication of ES2057756T3 publication Critical patent/ES2057756T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL ACIDO 3-OXIGERMILPROPIONICO [O SUB 1/2) SUB 3 GECH SUB 2 CH SUB 2 CO SUB 2 H] SUB N ("3-OGP") ES CONOCIDO COMO AGENTE FARMACOLOGICO, POR EJEMPLO, PARA EL TRATAMIENTO DE HEPATOPATIAS, PREFERENTEMENTE CON UN ESTABILIZADOR Y/O POTENCIADOR, PUDIENDO POSEER ACCIONES INMUNO-ACOMODATIVAS . SE HA DESCUBIERTO AHORA QUE EL 3-OGP ES EFECTIVO CONTRA UNA ENFERMEDAD AUTO-INMUNE DIABETICO-DEPENDIENTE Y ES UTILIZADO PARA LA FABRICACION DE MEDICAMENTOS PARA SU TRATAMIENTO O PREVENCION. UN PORTADOR ACTIVADOR, E. G. HIDROXIPROPILO ES NORMALMENTE UTILIZADO EN SU COMPOSICION, QUE PUEDE SER EN LA FORMA DE TABLETAS O CAPSULAS, EN LA CANTIDAD DE 0,0005 A 50% EN PESO DE 3-OGP. LA DOSIS RECOMENDADA DE LA COMPOSICION ES DE 10-1500 MG/KG, O UNA DIETA DE ADULTO DE CERCA DE 150 MG/DIA.
ES91301646T 1990-02-28 1991-02-28 Utilizacion del acido 3-oxigermilpropionico para tratar y prevenir enfermedades de autoinmunidad-diabetes dependientes. Expired - Lifetime ES2057756T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2048644A JPH03251526A (ja) 1990-02-28 1990-02-28 糖尿病依存型自己免疫疾患治療、予防用薬剤

Publications (1)

Publication Number Publication Date
ES2057756T3 true ES2057756T3 (es) 1994-10-16

Family

ID=12809074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91301646T Expired - Lifetime ES2057756T3 (es) 1990-02-28 1991-02-28 Utilizacion del acido 3-oxigermilpropionico para tratar y prevenir enfermedades de autoinmunidad-diabetes dependientes.

Country Status (5)

Country Link
US (1) US5180739A (es)
EP (1) EP0444931B1 (es)
JP (1) JPH03251526A (es)
DE (1) DE69103294T2 (es)
ES (1) ES2057756T3 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05255130A (ja) * 1992-03-16 1993-10-05 Asai Gerumaniumu Kenkyusho:Kk メイラード反応抑制改善剤
US5560925A (en) * 1993-11-09 1996-10-01 Sanwa Kagaku Kenkyusho Co., Ltd. Method of treating wart

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55122717A (en) * 1979-03-15 1980-09-20 Asai Gerumaniumu Kenkyusho:Kk Interferon inducer
JPS6041472A (ja) * 1983-08-16 1985-03-05 Refuorumu Syst Kk 美容・健康飲料
JPH0633242B2 (ja) * 1984-03-09 1994-05-02 株式会社三和化学研究所 有機ゲルマニウム化合物を有効成分とする肝炎の治療剤
JPH0643302B2 (ja) * 1984-09-07 1994-06-08 株式会社三和化学研究所 有機ゲルマニウム化合物の安定化方法
JPH0662407B2 (ja) * 1984-12-25 1994-08-17 株式会社三和化学研究所 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤
JPH0699304B2 (ja) * 1986-10-24 1994-12-07 株式会社三和化学研究所 ３―オキシゲルミルプロピオン酸を有効成分とする外用剤
JP3259976B2 (ja) * 1992-03-13 2002-02-25 株式会社放電精密加工研究所 金属防食剤

Also Published As

Publication number Publication date
EP0444931A3 (en) 1991-12-04
JPH03251526A (ja) 1991-11-11
EP0444931B1 (en) 1994-08-10
EP0444931A2 (en) 1991-09-04
DE69103294T2 (de) 1994-12-08
DE69103294D1 (de) 1994-09-15
US5180739A (en) 1993-01-19

Similar Documents

Publication Publication Date Title
KEYSTONE et al. Drugs five years later: Mebendazole
HUT45194A (en) Process for production of medical composition
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
FI943315A (fi) Farmaseuttinen valmiste pore- ja/tai hajoamistabletin tai pikarakeiden muodossa, samoin kuin menetelmä valmistaa niitä
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
DE60019436D1 (de) Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
KR970025615A (ko) 암 전이 억제제
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ES2057756T3 (es) Utilizacion del acido 3-oxigermilpropionico para tratar y prevenir enfermedades de autoinmunidad-diabetes dependientes.
KR920702225A (ko) 약학 조성물
ES2109208T1 (es) Nuevas aplicaciones de un dimero de lisozima.
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
MX9307479A (es) Uso de ciertos derivados de acido metanobisfosfonico en la curacion de fracturas.
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
KR930003913A (ko) 덱스트로메토르판의 진해효과를 증진시키기 위한 방법 및 약제학적 조성물
KR950700067A (ko) 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진의 동통 및 부종 치료용 용도(use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema)
ES2042831T3 (es) Procedimiento de preparacion de una composicion farmaceutica para el tratamiento de la osteoporosis.
KR920700626A (ko) 톡소플라스마병의 치료용 약제
US2907697A (en) Therapeutic compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 444931

Country of ref document: ES